Overexpression of KIF20A has been reported to be associated with cancer progression and chemoresistance in NSCLC, CRC and HCC (Zhao et al., 2018; Xie et al., 2020; Wu et al., 2021) Yang C. et al. (2021) reported that KIF20A induced NUAK1 activation upregulating GPX4 levels, which maintained intracellular redox homeostasis and inhibited ferroptosis, ultimately leading to CRC resistance to oxaliplatin. This evidence concerns the gene KIF20A and cancer.